香港联交所最新资料显示，10月6日，主席兼执行董事蔡东晨增持石药集团(01093)200万股，每股作价 为9.645港元，总金额为1929万港元。增持后最新持股数目约为28.37亿股，最新持股比例为24.62%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月6日，主席兼执行董事蔡东晨增持石药集团 (01093)200万股，每股作价为9.645港元，总金额为1929万港元。增持后最新持股数目约为28.37亿股， 最新持股比例为24.62%。 ...

Group 1 - The latest shareholder equity disclosure for Lion Rock Group (01127) and CSPC Pharmaceutical Group (01093) was conducted on October 6, 2025 [1] - Liu Zhujian increased his holdings in Lion Rock Group from 360 million shares to 362 million shares, representing a holding percentage increase from 46.70% to 46.99% [2] - Cai Dongchen slightly increased his holdings in CSPC Pharmaceutical Group from 2.834 billion shares to 2.835 billion shares, with a holding percentage increase from 24.59% to 24.61% [2]

| 股份代號: | 01093 | | --- | --- | | 上市法國名稱: | 石藥集國有限公 | | 日期 (日 / 月 / 年): | 06/09/2025 - 06 | 格隆汇10月6日丨根据联交所最新权益披露资料显示，2025年10月2日-10月3日，石药集团(01093.HK)获执行董事兼主席蔡东晨在场内以每股均价9.6238- 9.6383港元合计增持725.4万股，涉资约6989.8万港元。 增持后，蔡东晨最新持股数目为2,835,118,670股，持股比例由24.54%上升至24.61%。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原大 | 份數目 | | | (請參閱上述*註解)有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | ( % ) | | | DA20251003E00 ...

Core Insights - The latest shareholder equity disclosures for Electronic Trading Group (08036), Shenkong Holdings (00829), and CSPC Pharmaceutical Group (01093) were made on October 3, 2025 [1] Group 1: Electronic Trading Group (08036) - Shareholder 聂凡淇 reduced holdings from 98.04 million shares to 85.22 million shares, representing a decrease in ownership from 7.97% to 6.93% [2] - Financial Data Technologies Limited also reported the same reduction in holdings, confirming the decrease in ownership percentage [2] Group 2: Shenkong Holdings (00829) - Shareholder 周亚仙 increased holdings from 1.627 billion shares to 1.631 billion shares, resulting in a slight increase in ownership from 50.37% to 50.50% [2] Group 3: CSPC Pharmaceutical Group (01093) - Shareholder 蔡东晨 increased holdings from 2.828 billion shares to 2.834 billion shares, leading to a rise in ownership from 24.54% to 24.59% [2]

香港联交所最新资料显示，10月2日，主席兼执行董事蔡东晨增持石药集团(01093)600万股，每股作价 为9.6383港元，总金额为5782.98万港元。增持后最新持股数目约为28.34亿股，最新持股比例为 24.59%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月2日，主席兼执行董事蔡东晨增持石药集团 (01093)600万股，每股作价为9.6383港元，总金额为5782.98万港元。增持后最新持股数目约为28.34亿 股，最新持股比例为24.59%。 ...

恒生科技高开高走后维持在高位盘整，截至目前上涨2.5%。其中中芯国际大涨8.17%，快手上涨615%， 比亚迪电子上涨5.76%，蔚来上涨4.62%，华虹半导体上涨4.44%，百度集团、阿里巴巴等股涨幅均在 3%上方。 恒生工商也有不错表现，截至目前上涨2.1%。其中信义光能大涨9.01%，申洲国际上涨7.92%，中升控 股上涨4.46%，翰森制药上涨4.38%，紫金矿业、石药集团、药明生物等股涨幅均在3%附近。 内房地低开低走大跳水，截至目前下跌2.34%。其中贝壳大跌5.38%，龙湖集团下跌3.45%，建发国际集 团下跌2.85%，华润置地下跌2.24%，越秀地产、九龙仓集团、华润万象生活等股跌幅均在1%上方。 内银行相对弱势但出现了止跌企稳的迹象，截至目前已回到中轴附近。其中重庆农村商业银行大跌 2%，招商银行、农业银行、建设银行等股小幅下跌；民生银行上涨1.7%，交通银行、工商银行、中国 银行等股均小幅上涨。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数开盘后直线拉升，截至目前上涨1.41%。其中恒生科技涨幅居前，工商、国指ESG、内石油等 涨幅居前；内房地 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 石藥集團有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01093 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 11,521,951,732 | | 0 | | 11,521,951,732 | | 增加 / 減少 (-) | | | 50 ...

Core Viewpoint - The Hong Kong stock market for innovative drug concepts has strengthened, with significant gains in various pharmaceutical companies following the postponement of drug tariffs by the Trump administration [1] Group 1: Market Performance - Companies such as Kelun-Biotech and Gilead Sciences saw their stock prices rise over 8% - Hengrui Medicine increased by over 6% - Companies like Tongyuan Kang Pharmaceutical and Xiansheng Pharmaceutical rose over 5% - Hansoh Pharmaceutical and Innovent Biologics gained over 4% - Companies such as Sihuan Pharmaceutical, Fuxing Pharmaceutical, Shiyao Group, and 3SBio increased by over 3% [1] Group 2: Regulatory Environment - President Trump had previously threatened to impose three-digit tariffs on drug imports starting Wednesday, but the White House indicated that these tariffs may not need to be implemented [1] Group 3: Industry Insights - Pacific Securities released a research report suggesting that attention should be paid to several factors: 1) Changes in Federal Reserve interest rate policies 2) Marginal changes in investment and financing 3) Gradual recovery of overseas demand 4) Sino-US relations and geopolitical factors 5) Class B medical insurance directory and commercial insurance [1]